Angiogenic gene therapy - Transgene

Drug Profile

Angiogenic gene therapy - Transgene

Alternative Names: AD-CTGF2

Latest Information Update: 23 Aug 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Transgene
  • Class
  • Mechanism of Action Angiogenesis inducing agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Ischaemic heart disorders; Peripheral arterial disorders

Most Recent Events

  • 23 Aug 2007 No development reported - Preclinical for Ischaemic heart disorders in France (Injection)
  • 23 Aug 2007 No development reported - Preclinical for Peripheral arterial disorders in France (Injection)
  • 30 Jun 2003 Ad-CTGF2 is available for licensing (www.transgene.fr)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top